[10-1] Hordeaux J, et al. The neurotropic properties of AAV-PHP.B are limited to C57BL/6J mice. Mol Ther. 2018;26:664-668. DOI:10.1016/j.ymthe.2018.01.018. PMID:29428298. [H]
[10-2] Challis RC, et al. Systemic AAV vectors for widespread and targeted gene delivery in rodents. Nat Protoc. 2019;14:379-414. DOI:10.1038/s41596-018-0097-3. PMID:30626963. [H]
[10-3] Huang Q, et al. An AAV capsid reprogrammed to bind human transferrin receptor mediates brain-wide gene delivery. Science. 2024;384:1220-1227. DOI:10.1126/science.adm8386. PMID:38753766. [N]
[10-4] Tabebordbar M, et al. Directed evolution of AAV capsids enabling potent muscle delivery across species. Cell. 2021;184:4919-4938.e22. DOI:10.1016/j.cell.2021.08.028. [H]
[10-5] Pillay S, Meyer NL, Puschnik AS, et al. An essential receptor for adeno-associated virus infection. Nature. 2016;530(7588):108-112. DOI:10.1038/nature16465. PMID:26842050. [H]
[10-6] Kaludov N, Brown KE, Walters RW, Zabner J, Chiorini JA. AAV4 and AAV5 both require sialic acid binding but differ in sialic acid linkage specificity. J Virol. 2001;75(15):6884-6893. DOI:10.1128/JVI.75.15.6884-6893.2001. PMID:11435570. [H]
[10-7] Wu Z, Miller E, Agbandje-McKenna M, Samulski RJ. Alpha2,3 and alpha2,6 N-linked sialic acids facilitate binding and transduction by AAV types 1 and 6. J Virol. 2006;80(18):9093-9103. DOI:10.1128/JVI.00895-06. PMID:16940520. [H]
[10-8] Summerford C, Samulski RJ. Membrane-associated heparan sulfate proteoglycan is a receptor for AAV type 2 virions. J Virol. 1998;72(2):1438-1445. PMID:9445046. [H]
[10-9] Mietzsch M, et al. Natural AAV serotypes and engineered AAV capsid variants: tropism differences and mechanistic insights. Viruses. 2024;16(3):442. DOI:10.3390/v16030442. [N]
[10-10] Ling C, et al. Heparan sulfate proteoglycan binding of AAV3 (R594). See [10-9] for review. [H]
[10-11] Kaludov N, et al. AAV4 uses alpha2-3 O-linked sialic acid. J Virol. 2001;75:6884-6893 [Same as 10-6]. [H]
[10-12] Dudek AM, Pillay S, Puschnik AS, et al. Alternative fates of AAV entry independent of AAV receptor (AAV4 Clade G). J Virol. 2018;92(8):e02213-17. DOI:10.1128/JVI.02213-17. PMID:29343568. [N]
[10-13] Walters RW, Yi SM, Keshavjee S, et al. Binding of AAV type 5 to 2,3-linked sialic acid is required for gene transfer. J Biol Chem. 2001;276(23):20610-20616. DOI:10.1074/jbc.M101559200. [H]
[10-14] Di Pasquale G, Davidson BL, Stein CS, et al. Identification of PDGFR as a receptor for AAV-5 transduction. Nat Med. 2003;9(10):1306-1312. DOI:10.1038/nm929. PMID:14502278. [H]
[10-15] Wu Z, Asokan A, Samulski RJ. Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther. 2006;14(3):316-327. DOI:10.1016/j.ymthe.2006.05.009. PMID:16820342. [H]
[10-16] Weller ML, Amornphimoltham P, Schmidt M, Wilson PA, Gutkind JS, Chiorini JA. EGFR is a co-receptor for AAV serotype 6. Nat Med. 2010;16(6):662-664. DOI:10.1038/nm.2145. [H]
[10-17] Dhungel BP, Xu H, Nagarajah R, et al. An alternate receptor for adeno-associated viruses (CPD/AAVR2). Cell. 2025. DOI:10.1016/j.cell.2025.06.026. [N]
[10-18] Shen S, Bryant KD, Brown SM, Randell SH, Asokan A. Terminal N-linked galactose is the primary receptor for AAV9. J Biol Chem. 2011;286(15):13532-13540. DOI:10.1074/jbc.M110.192317. [H]
[10-19] Bell CL, Gurda BL, Van Vliet K, Agbandje-McKenna M, Wilson JM. Identification of the galactose binding domain of the AAV9 capsid. J Virol. 2012;86(13):7326-7333. DOI:10.1128/JVI.00321-12. [H]
[10-20] Grimm D, et al. In vitro recombination yields AAV-DJ / AAV-LK03 chimeras. (AAV-DJ: Nat Biotechnol. 2008;26:517-518; LK03: Nature. 2014;506:382-386.) [H]
[10-21] Chan KY, Jang MJ, Yoo BB, et al. Engineered AAVs for efficient noninvasive gene delivery to the CNS and PNS (PHP.eB/PHP.S). Nat Neurosci. 2017;20(8):1172-1179. DOI:10.1038/nn.4593. PMID:28671695. [H]
[10-22] Deverman BE, Pravdo PL, Simpson BP, et al. Cre-dependent selection yields AAV variants for widespread adult brain gene transfer (PHP.B). Nat Biotechnol. 2016;34(2):204-209. DOI:10.1038/nbt.3440. PMID:26779325. [H]
[10-23] Identification of CD164 as an essential entry receptor for divergent AAVs. PNAS. 2026. DOI:10.1073/pnas.2525865123. [N]
[10-24] Zengel D, et al. Hardwiring tissue-specific AAV transduction in mice through engineered receptor expression (conditional AAVR). 2023. [N]
[10-25] Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, Kaspar BK. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol. 2009;27(1):59-65. DOI:10.1038/nbt.1515. PMID:19098895. [H]
[10-26] Zincarelli C, Soltys S, Rengo G, Rabinowitz JE. Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther. 2008;16(6):1073-1080. DOI:10.1038/mt.2008.76. PMID:18414476. [H]
[10-27] Yang (CAS) et al. A comprehensive study of AAV tropism across C57BL/6 mice, BALB/c mice, and crab-eating macaques (21 capsid barcoded IV pool, 5×10^12 vg/kg). 2024. PMC11919325. [N]
[10-28] Bish LT, Morine K, Sleeper MM, et al. AAV9 provides global cardiac gene transfer superior to AAV1/6/7/8 in mouse and rat. Hum Gene Ther. 2008;19(12):1359-1368. DOI:10.1089/hum.2008.123. PMID:18729825. [H]
[10-29] Halbert CL, Allen JM, Miller AD. AAV6 vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to AAV2. J Virol. 2001;75(14):6615-6624. DOI:10.1128/JVI.75.14.6615-6624.2001. PMID:11413329. [H]
[10-30] AAV vectors for retinal gene therapy (SR tropism AAV1/2/4/5/8). Front Med. 2022;10:1310050. PMC10722277. [N]
[10-31] Recombinant AAV as delivery platform for ocular gene therapy (AAV8 photoreceptors > AAV2). 2024. PMC11638839. [N]
[10-32] Issa SS, et al. AAV5 astrocyte/CNS tropism review. Cells. 2023;12(5):785. DOI:10.3390/cells12050785. [H]
[10-33] Muraine L, et al. Transduction efficiency of AAV serotypes after local injection in mouse and human skeletal muscle. Hum Gene Ther. 2020;31(3-4):233-240. DOI:10.1089/hum.2019.173. [N]
[10-34] Palomeque J, et al. Comparative cardiac gene delivery of AAV serotypes 1-9 (AAV6 most efficient mouse heart). Gene Ther. 2009. PMC3962265. [H]
[10-35] Cunningham SC, et al. (AAV8 liver hepatocyte, cross-species). Mol Ther. 2008;16:1081-1088. [H]
[10-36] Tenaya Therapeutics comparative poster: AAV9 vs AAVrh.10 vs AAVrh.74 cardiomyocyte transduction in NHP. 2023. [N]
[10-37] Mendell JR, et al. Assessment of systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in DMD. JAMA Neurol. 2020;77(9):1-10. DOI:10.1001/jamaneurol.2020.1484. [N]
[10-38] ELEVIDYS (delandistrogene moxeparvovec-rokl) FDA label, AAVrh74 micro-dystrophin for DMD. 2023/2024. [N]
[10-39] Tropism and retinal transduction efficiency of AAV serotypes in mice (AAV-DJ RPE, AAV2.7m8). 2024. PMC12422392. [N]
[10-40] Hordeaux J, Wang Q, Katz N, Buza EL, Bell P, Wilson JM. The neurotropic properties of AAV-PHP.B are limited to C57BL/6J mice. Mol Ther. 2018;26(3):664-668. DOI:10.1016/j.ymthe.2018.01.018. PMID:29429743. [H]
[10-41] Batista AR, et al. Neurotropic properties of AAV-PHP.B are shared among diverse inbred strains of mice. Mol Ther. 2019. PMC6453512. [N]
[10-42] Huang QY, et al. Delivering genes across the blood-brain barrier: LY6A, a novel cellular receptor for AAV-PHP.B capsids. PLoS One. 2019;14(11):e0225206. DOI:10.1371/journal.pone.0225206. [N]
[10-43] Huang Q, et al. An AAV capsid reprogrammed to bind human transferrin receptor mediates brain-wide gene delivery (BI-hTFR1). Science. 2024;384(6702):1220-1227. DOI:10.1126/science.adm8386. PMID:38187643. [N]
[10-44] Tabebordbar M, Lagerborg KA, Stanton A, et al. Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species (MyoAAV). Cell. 2021;184(19):4919-4938.e22. DOI:10.1016/j.cell.2021.08.028. PMID:34506722. [H]
[10-45] Liver injury in cynomolgus monkeys following IV and intrathecal scAAV9 gene therapy. 2023. PMC10556189. [N]
[10-46] Dehay B, et al. Systemic scAAV9 in fetal macaques neuronal CNS/PNS transduction. Gene Ther. 2013;20:69-83. DOI:10.1038/gt.2011.216. [H]
[10-47] AAV2.7m8 retinal intravitreal transduction up to ~60% photoreceptors. Front Neurosci. 2020;14:570909. [N]
[10-48] Jang MJ, et al. Spatial transcriptomics for profiling the tropism of viral vectors in tissues. Nat Biotechnol. 2023;41(9):1272-1286. DOI:10.1038/s41587-022-01648-w. [N]
[10-49] Tervo DGR, Hwang BY, Viswanathan S, et al. A designer AAV variant permits efficient retrograde access to projection neurons (AAV2-retro). Neuron. 2016;92(2):372-382. DOI:10.1016/j.neuron.2016.09.021. [H]
[10-50] Choudhury GR, et al. AAV.CAP-B10/B22 brain-wide expression and decreased liver targeting in mouse and marmoset. Nat Neurosci. 2022;25:106-115. DOI:10.1038/s41593-021-00969-4. [N]
[10-51] Pulicherla N, et al. In vivo selection yields AAV-B1 capsid for CNS and muscle gene therapy. Mol Ther. 2016;24:1247-1257. DOI:10.1038/mt.2016.84. [N]
[10-52] Weinmann J, et al. Semirational bioengineering of AAV vectors (AAVMYO, RGDLGLS P1 peptide) muscle delivery. PMC9491714 / PMC12451274. [N]
[10-53] Challis RC, et al. Systemic AAV vectors for widespread and targeted gene delivery in rodents. Nat Protoc. 2019;14(2):379-414. DOI:10.1038/s41596-018-0097-3. [F]